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BACKGROUND: The extent to which experiencing a stressful life event influences breast cancer prognosis remains unknown,
as the findings of the few previous epidemiological studies are inconsistent. This large population-based study examines the
association between a common major life event, loss of a partner and breast cancer recurrence and all-cause mortality.
METHODS: N¼ 21 213 women diagnosed with a first primary breast cancer 1994–2006, who had a cohabiting partner in the 4 years
before their breast cancer diagnosis, were followed for death and recurrence in population-based registers and clinical databases.
Information on education, disposable income, comorbidity and prognostic risk factors were included in Cox regression analyses.
RESULTS: Women who had lost a partner either before diagnosis or in subsequent years were not at significantly higher risk
of recurrence or dying than women who had not lost a partner.
CONCLUSION: Our results do not support the concern that experiencing a stressful life event, the loss of a partner, negatively affects
prognosis of breast cancer.
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A stressful life event may affect prognosis of breast cancer directly
through stress-induced alterations of the immune and neuroendo-
crine system and indirectly through changes in health behaviour,
such as physical activity, consumption of alcohol, compliance to
therapy and coping with disease. In all, six previous studies have
addressed the association between stressful life events and breast
cancer prognosis: two of which found a significantly increased risk
for recurrence (Ramirez et al, 1989; Palesh et al, 2007), two studies
found no association (Hislop et al, 1987; Maunsell et al, 2001),
whereas two studies found, contrary to what was expected, a
significantly lower risk of recurrence (Barraclough et al, 1992;
Graham et al, 2002). These inconsistent findings may be due to the
use of different measures of exposure and methodological
weaknesses including self-reported measure of exposure,
small samples (N¼ 94–665) and selection or recall bias (refer to
web appendix: Supplementary Table A1). In this large popu-
lation-based study, of more than 20 000 breast cancer cases,
we use objective information from population-based registers and
clinical databases to examine the association between a single life
event stressor, loss of a partner and breast cancer prognosis.
Loss of a partner is a common and also very stressful life
event, implying considerable changes to everyday life (Holmes and
Rahe, 1967).
MATERIALS AND METHODS
Linkage of registry data
Information on sex, date of birth, current and historical addresses,
emigration, disappearance and death with date of these incidences
were obtained from the Central Population Register in which all
Danish residents since 1968 have been registered with a personal
identification number allowing linkage of information between
national registers (Pedersen et al, 2006).
Breast cancer
We obtained information on date of breast cancer diagnosis
(defined as date of primary surgery), date of recurrence (which is
reported up to 10 years after diagnosis), tumour size (in mm),
number of tumour-positive lymph nodes, malignancy grade,
hormone receptor status and menopausal status, from Danish
Breast Cancer Cooperative Group, which contain information
on nearly 95% of all breast cancer cases in Denmark since 1977
(Møller et al, 2008).
Other cancers
Information on first primary cancer, excluding nonmelanoma skin
cancer, was obtained from the Danish Cancer Registry, which since
1943 have registered all cases of cancer (ICD-7) in Denmark
(Storm et al, 1997).
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Stressful life event
A stressful life event was defined as the death of a cohabiting partner
either in the 4 years before breast cancer diagnosis or in subsequent
years. ‘Cohabitation’ was defined as two persons of the opposite sex
over the age of 16, with a maximum age difference of 15 years, living
at the same address with no other adults in the residence.
Socioeconomic status and comorbidity
Information on educational level and disposable income (cate-
gorised in Table 1) was obtained 2 years before breast cancer
diagnosis from the population-based Integrated Database for
Labour Market Research in Statistics Denmark with data on
sociodemographic factors in Denmark since 1980 (Thygesen, 1995).
Information on comorbidity categorised according to the
Charlson comorbidity index (scores 0, 1 and X2), excluding
cancers (Charlson et al, 1987) was obtained from the Danish
National Patient Register with information on all somatic diseases
leading to hospitalisation since 1977, and from 1995 also
information on all outpatient visits (Andersen et al, 1999).
Analysed cohort
To attain accurate information from the included registers our
base population is restricted to all 3.4 million Danish residents
born between 1925 and 1973 who resided in Denmark 1994–2006
and entered the cohort at age 30 (for more details Dalton et al,
2008). From this population we identified 22 366 women diagnosed
with breast cancer between 1 January 1994 and 31 December 2006
with no previous history of cancer (except nonmelanoma skin
cancer), who resided in Denmark 2 years before diagnosis, and
had a cohabiting partner up to 4 years before their breast cancer
diagnosis. We excluded 1153 women with missing values on one
or more covariates or who had resided in Denmark for less than
2 years. In all, 21 213 eligible women were followed for recurrence
and death.
Statistical analyses
We used Cox regression to assess hazard ratios (HRs) with 95%
confidence intervals (CIs) for all-cause mortality and breast cancer
recurrence, respectively, according to the vital status of the
partner. For all-cause mortality follow-up time was counted from
the date of diagnosis until death, emigration or 31 December 2010,
whichever came first. For breast cancer recurrence follow-up time
was counted from the date of diagnosis until death, emigration,
10 years of follow-up or 31 December 2006, whichever came first.
The exposure, death of partner (after diagnosis), was included as a
time-dependent variable, so that person–time before the death of
the partner was counted as unexposed, whereas person–time after
the date of death of the partner was counted as exposed. In all
analyses, time since breast cancer diagnosis was used as the
underlying time scale, and baseline hazards were allowed to vary
across age at breast cancer diagnosis in 1-year intervals. The HRs
were first adjusted for educational level and income, both
considered as potential confounders. Subsequently, we adjusted
for comorbidity, period of diagnosis, tumour size, number
of positive lymph nodes, receptor status and malignancy grade
(I–IV), as these factors are strongly associated with outcome,
however, not obviously associated with the exposure. We
estimated HRs in the intervals [0–1],]1–2],]3–4] years for exposure
before diagnosis and for latencies of: [0–2],] 2–5],]5–17] years for
exposure after diagnosis. We investigated whether a change in
cohabitation status influenced the estimated association, by
censoring at 1 January in the year in which the cohabitation
status changed. Further, we estimated the association for women
Table 1 Descriptive characteristics at entry of 21 213 women with
breast cancer diagnosed in 1994–2006, Denmark, by vital-status of the
partner at exit
Partner’s
death before
diagnosis
(n¼ 762),
No. (%)
Partner’s
death after
diagnosis
(n¼2259),
No. (%)
Partner
alive
at exit
(n¼18 192),
No. (%)
Sociodemographic characteristics
Age at time of diagnosis (years)
30–39 2 (1) 25 (1) 1266 (7)
40–49 40 (5) 219 (10) 4640 (26)
50–59 154 (20) 670 (30) 6926 (38)
60–69 385 (51) 1061 (47) 4501 (25)
X70 181 (24) 284 (13) 859 (5)
Mean/median 64/65 60/61 54/54
Level of educationa
Basic or high school 440 (58) 1204 (53) 7127 (39)
Vocational education 227 (30) 703 (31) 6551 (36)
Higher education 95 (12) 352 (16) 4514 (25)
Disposable incomeb
Lowest (1st quartile) 340 (45) 536 (24) 2489 (14)
Middle (2nd–3rd quartile) 308 (40) 1107 (49) 8468 (47)
Highest (4th quartile) 114 (15) 616 (27) 7235 (40)
Medical characteristics
Tumour size (mm)
0–10 98 (13) 415 (18) 2851 (16)
11–20 297 (39) 963 (43) 7352 (40)
21–50 311 (41) 780 (35) 6560 (36)
X51 22 (3) 53 (2) 737 (4)
Unknown 34 (4) 48 (2) 692 (4)
No. of positive lymph nodes
0 393 (52) 1323 (59) 8979 (49)
1–3 204 (27) 644 (29) 5380 (30)
X4 140 (18) 274 (12) 3434 (19)
Unknown 25 (3) 18 (1) 399 (2)
Malignancy grade
Grade I 186 (24) 660 (29) 4197 (23)
Grade II 261 (34) 738 (33) 6248 (34)
Grade III 130 (17) 321 (14) 3795 (21)
Grade IV 49 (6) 85 (4) 861 (5)
Unknown 136 (18) 455 (20) 3091 (17)
ER and PR Statusc
Negative 129 (17) 380 (17) 3882 (21)
Positive 588 (77) 1733 (77) 13 254 (73)
Unknown 45 (6) 146 (6) 1056 (6)
Period of diagnosis
1994–1996 49 (6) 608 (27) 3100 (17)
1997–1999 134 (18) 557 (25) 3792 (21)
2000–2002 217 (28) 580 (26) 4527 (25)
2003–2006 362 (48) 514 (23) 6773 (37)
Charlson comorbidity indexd
0 603 (79) 1976 (87) 16 334 (90)
1 100 (13) 176 (8) 1201 (7)
X2 59 (8) 107 (5) 657 (4)
aHighest-education attained 2 years before diagnosis: basic school/high school
(7–12 years of primary, secondary and grammar school); vocational training (10–12
years of education); higher education (X13 years of education). bDisposable income
extracted 2 years before diagnosis; income quartiles calculated according to the
entire population in the investigated age group, after taxation and interest per person,
adjusted for number of people in the household and deflated according to the 2000
value of the Danish crown, as: deflated household income/(no. of person
in household 0.6). cNegative indicates that individual was estrogen receptor
(ER) and progesterone receptor (PR) negative. Positive indicates ER-positive or
PR-positive. dAccumulated value of all hospital contacts from 1978 to date of
diagnosis; scores weighted by level of severity assigned to 19 conditions (excluding
cancers) and grouped on the basis of the cumulated sum of scores of 0, 1 and X2.
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diagnosed with hormone-receptor-positive breast cancer and post-
menopausal women only.
RESULTS
In the analysis of the association between loss of partner and all-
cause mortality 172 773 person–years of follow-up were accrued,
with a median follow-up of 7.7 years (ranging 0–17). During
follow-up, 5660 women died, 762 lost their partner in the 4 years
before their breast cancer diagnosis and 2259 lost their partner
during follow-up. As expected, women who lost their partner were
older and had a lower education and income compared with those
who did not (Table 1). After adjustment for education and income
as well as period of diagnosis, comorbidity and severity of breast
cancer, women who had lost a partner were not at a significantly
higher risk for recurrence or all-cause death from that of women
who did not lose a partner, no matter if the event happened in the
4 years before diagnosis or in subsequent years (Table 2) or at
different latencies (Table 3). We found only minor changes to the
estimates when censoring at change in cohabitation status and
when measuring the association only among women diagnosed
with hormone-receptor-positive breast cancer or post-menopausal
women (results not shown).
DISCUSSION
Our results do not support the concern that experiencing a major
stressful life event, loss of a partner, negatively affects breast
Table 3 Hazard ratios (HRs) for death and their 95% confidence intervals (CIs) according to partner’s vital status and time between diagnosis, death and
death of partner among 21 213 women with breast cancer diagnosed in 1994–2006, Denmark
Crudea Adjusted HRb Adjusted HRc
N Person years Events HRd (95% CI) HRd (95% CI) HRd (95% CI)
All-cause mortality
Exposure before diagnosis
Time from bereavement to diagnosis (years)
[0 – 1] 228 1610 76 1.17 (0.93, 1.48) 1.15 (0.91, 1.44) 1.04 (0.82, 1.34)
]1 –2] 195 1391 65 1.14 (0.89, 1.46) 1.04 (0.81, 1.34) 1.05 (0.80, 1.38)
]2 –4] 339 2215 102 1.11 (0.91, 1.36) 1.04 (0.85, 1.26) 1.19 (0.96, 1.47)
Exposure after diagnosis
Time from bereavement to death (years)
[0 – 1] 647 5768 173 1.20 (0.98, 1.48) 1.16 (0.95, 1.43) 1.11 (0.89, 1.39)
[1 –5] 766 7237 156 1.11 (0.97, 1.28) 1.08 (0.94, 1.23) 1.09 (0.94, 1.26)
45 846 10142 111 1.07 (0.88, 1.31) 1.04 (0.85, 1.27) 1.08 (0.87, 1.34)
Recurrence
Exposure before diagnosis
Time from bereavement to diagnosis (years)
[0 – 1] 228 904 15 0.66 (0.40, 1.10) 0.66 (0.39, 1.09) 0.57 (0.32, 1.01)
[1 –2] 195 800 14 0.71 (0.42, 1.20) 0.69 (0.41, 1.17) 0.74 (0.42, 1.32)
[2 –4] 339 1135 30 1.05 (0.73, 1.51) 1.03 (0.72, 1.49) 1.11 (0.74, 1.65)
Exposure after diagnosis
Time from bereavement to death (years)
[0 – 1] 467 2439 48 0.90 (0.61, 1.34) 0.90 (0.60, 1.33) 0.73 (0.46, 1.17)
[1 –5] 412 2837 28 1.01 (0.76, 1.34) 1.00 (0.75, 1.33) 1.01 (0.75, 1.36)
45 260 2306 9 1.02 (0.52, 2.00) 1.02 (0.52, 2.00) 1.16 (0.57, 2.37)
aStratified by age at diagnosis in 1-year intervals. bAdjusted for the highest-attained educational level, disposable income and stratified by age at diagnosis in 1-year intervals.
cAdjusted for the highest-attained educational level, disposable income, period of diagnosis, comorbidity, tumour size, no. of tumour-positive lymph-nodes, hormone receptor
status, malignancy grade and stratified by age at diagnosis in 1-year intervals (N¼ 19 186) (defined in Table 1). dThe reference category (HR¼ 1) are not experiencing the death
of a cohabiting partner in the given year-interval.
Table 2 Hazard ratios (HRs) for death and recurrence with 95% confidence intervals (CIs) according to partner’s vital status among 21 213 women with
breast cancer diagnosed in 1994–2006, Denmark
Crudea Adjusted HRb Adjusted HRc
N Person years Events HR (95% CI) HR (95% CI) HR (95% CI)
All-cause mortality
Partner alive at exit (ref.) 18 192 144 410 4977 1.00 1.00 1.00
Exposed in the 4 years before diagnosis 762 5216 243 1.14 (1.00, 1.30) 1.07 (0.94, 1.22) 1.10 (0.95, 1.27)
Exposed 0–17 years after diagnosis 2259 23 147 440 1.12 (1.01, 1.25) 1.09 (0.98, 1.20) 1.09 (0.98, 1.22)
Recurrence
Partner alive at exit (ref.) 19 312 86 453 2635 1.00 1.00 1.00
Exposed in the 4 years before diagnosis 762 2839 59 0.83 (0.64, 1.08) 0.82 (0.63, 1.06) 0.82 (0.61, 1.09)
Exposed 0–17 years after diagnosis 1139 7581 85 0.98 (0.78, 1.22) 0.97 (0.78, 1.21) 0.93 (0.73, 1.18)
aStratified by age at diagnosis in 1-year intervals. bAdjusted for the highest-attained educational level, disposable income, and stratified by age at diagnosis in 1-year intervals
(defined in Table 1). cAdjusted for the highest-attained educational level, disposable income, period of diagnosis, comorbidity, tumour size, no. of tumour-positive lymph-nodes,
hormone receptor status, malignancy grade and stratified by age at diagnosis in 1-year intervals (N¼ 19 186) (defined in Table 1).
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cancer recurrence or all-cause mortality, whether the event occurs
in the 4 years before or 0–17 years after diagnosis. Of six previous
studies four support this finding (Hislop et al, 1987; Barraclough
et al, 1992; Maunsell et al, 2001; Graham et al 2002). Two previous
studies found a higher risk of recurrence among women reporting
stressful life events, however, both were of retrospective design and
the observed estimate may reflect differential recall and reporting
of events (Ramirez et al, 1989; Palesh et al, 2007).
We addressed several methodological limitations of the previous
studies. First, we included more than 30 times as many cancer
patients as the largest study published so far. Second, the use of
national registers and databases to identify the study population
ensures high representativeness and minimal risk for selection
bias. Third, the exposure (death of partner) was measured
independently of the participants, eliminating recall bias. Fourth,
the register-based cohort design ensures temporality and mini-
mises loss to follow-up and misclassification of outcomes. Finally,
we estimated the effect of the death of partner before and after
diagnosis on both recurrence and all-cause mortality.
Still, loss of partner is relatively rare among newly diagnosed
breast cancer patients, and 73% of the cohort was alive
and recurrence free at exit, resulting in small number of events in
certain subgroups. The observed estimates of all-cause mortality may
represent overestimates of breast cancer-specific mortality. We
adjusted, however, the analyses for comorbidity and investigated also
recurrence as outcome. Finally, an association may be present
among women with poor coping resources or accumulated stressful
life events. We were unable to take these into account.
The death of a partner is a common major life event, and our
finding of no association with breast cancer recurrence or all-cause
mortality may provide reassurance for women confronting breast
cancer.
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